Tamoxifen and the uterus

European Journal of Cancer

Volumn 34, Issue SUPPL. 4, 1998, Pages

  Vergote, I ^a   Neven, P ^a   Vanderick, G ^a   Van Dam, P ^a   Van Belle, Y ^a   De Sutter, Ph ^a   De Prins, F ^a   De Muylder, X ^a   Claerhout, J ^a   Campo, R ^a   Albertyn, G ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

TAMOXIFEN;

BREAST CANCER; CANCER INCIDENCE; CANCER PREVENTION; CANCER SCREENING; CARCINOGENESIS; CONFERENCE PAPER; ENDOMETRIUM CANCER; PRIORITY JOURNAL; PUBLICATION;

ANTINEOPLASTIC AGENTS, HORMONAL; CARCINOGENS; ENDOMETRIAL NEOPLASMS; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; TAMOXIFEN; UTERUS;

EID: 0031719273     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(98)00174-9     Document Type: Conference Paper

References (42)

1. T Fornander L.E. Rutqvist B Cedermark Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers Lancet 1 1989 117 120
2. T.J. Powles Tamoxifen's oestrogen-like effects in a breast cancer chemoprevention trial Eur J Cancer 34 Suppl. 4 1998 S17 S18
3. X De Muylder P Neven Y Van Belle Tamoxifen and benign endometrial lesions Eur J Cancer 34 Suppl. 4 1998 S18 S19
4. S.M. Ismail Significance of benign uterine pathology on tamoxifen Eur J Cancer 34 Suppl. 4 1998 S26 S27
5. G Le Bouedec M De Latour J. Dauplat Tamoxifen and uterine fibroids Eur J Cancer 34 Suppl. 4 1998 S19 S21
6. D Timmerman J Deprest T Bourne I Van den Berghe W.P. Collins I Vergote Saline infusion sonography (SIS) or office hysteroscopy: which one is the best? A prospective randomised study Eur J Cancer 34 Suppl. 4 1998 S32 S33
7. M.J.E. Mourits E.G.E. de Vries P.H.B. Willemse Is ovarian cyst formation related to tamoxifen use? Eur J Cancer 34 Suppl. 4 1998 S21 S22
8. I. Cohen Tamoxifen and other genital tissues: vagina, cervix and ovaries Eur J Cancer 34 Suppl. 4 1998 S22 S23
9. L Schwanz Alterations in steroid hormone receptors in the tamoxifen-treated endometrium Eur J Cancer 34 Suppl. 4 1998 S23 S24
10. G Dallenbach-Hellweg D Schmidt The progestin-like activity of tamoxifen on the endometrium Eur J Cancer 34 Suppl. 4 1998 S24 S25
11. International Agency for Research on Cancer IARC Monographs on the evaluation of carcinogenic risks to humans. Volume 66. Some pharmaceutical drugs 1996 International Agency for Research on Cancer Lyon
12. A.J. Sasco Tamoxifen, a human carcinogen or the share of common risk factors? Eur J Cancer 34 Suppl. 4 1998 S43 S44
13. F Van Leeuwen L Bergman J Benraadt Does risk of endometrial cancer increase with longer duration of tamoxifen use? Eur J Cancer 34 Suppl. 4 1998 S44 S45
14. L Bernstein J Cerhan S Schwartz J Liff J Perlman L Ford The combined effects of ERT, obesity and tamoxifen therapy for breast cancer on endometrial cancer risk Eur J Cancer 34 Suppl. 4 1998 S46
15. H Mignotte C Lasset V Bonadona Iatrogenic risks of endometrial carcinoma after treatment for breast cancer in a large French case-control study Eur J Cancer 34 Suppl. 4 1998 S46 S47
16. V.C. Jordan Tamoxifen and uterine cancer: confounding variables Eur J Cancer 34 Suppl. 4 1998 S50 S51
17. M. Baum Tamoxifen and the breast Eur J Cancer 34 Suppl. 4 1998 S7 S8
18. U Magriples F Naftolin P.E. Schwartz High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients J Clin Oncol 11 1993 485 490
19. I Van Hooff High grade endometrial cancer associated with tamoxifen use Eur J Cancer 34 Suppl. 4 1998 S48 S49
20. R Barakat Tamoxifen and endometrial cancer: most cancers are early stage and highly curable Eur J Cancer 34 Suppl. 4 1998 S49 S50
21. J. Bonte Tamoxifen to treat endometrial cancer Eur J Cancer 34 Suppl. 4 1998 S51 S52
22. E.A. Martin I.N.H. White K.W. Turteltau L.L. Smith Identification of tamoxifen-DNA adducts Eur J Cancer 34 Suppl. 4 1998 S65 S66
23. K Hemminki Tamoxifen H. Rajaniemi DNA adducts in breast cancer patients Eur J Cancer 34 Suppl. 4 1998 S66
24. P.L. Carmichael S Sardar P Neven Detection of DNA adducts in the human endometrium: a lack of evidence Eur J Cancer 34 Suppl. 4 1998 S66 S67
25. D.H. Phillips W Davis S Venitt H Glatt Tamoxifen metabolism and activation: the reason for interspecies differences Eur J Cancer 34 Suppl. 4 1998 S13 S14
26. M Pollak Effects of anti-oestrogens on insulin-like growth factor (IGF-I) physiology systemically and in the uterus Eur J Cancer 34 Suppl. 4 1998 S11 S12
27. E Tomás Does the human uterus agree with existing models? Experiences with insulin-like growth factor (IGF) Eur J Cancer 34 Suppl. 4 1998 S12 S13
28. P.L. Carmichael J.J. Mills P Neven An epigenetic mechanism for tamoxifen-associated uterine carcinogenesis? Eur J Cancer 34 Suppl. 4 1998 S10 S11
29. H Van Den Berghe Cytogenetic changes in endometrial polyps from tamoxifen users Eur J Cancer 34 Suppl. 4 1998 S63
30. B Moberger T Fornander A.C. Hellström DNA content in tamoxifen-induced endometrial carcinoma Eur J Cancer 34 Suppl. 4 1998 S64
31. D Franchi N.N. Colombo L Bocciolone A Maggioni A Costa V Sacchini Tamoxifen and the uterus: potential uterine risks of anti-oestrogens. The approach of the European Institute of Oncology Eur J Cancer 34 Suppl. 4 1998 S34 S35
32. S.J.M. Neele W.M. van Baal M.J. van der Mooren P Kenemans J.C. Netelenbos Saline infusion sonography is a good approach for additional assessment of the endometrium Eur J Cancer 34 Suppl. 4 1998 S35 S36
33. Y Van Belle R Campo P Neven X De Muylder G. Vanderick Tamoxifen and the uterus—the hysteroscopic approach Eur J Cancer 34 Suppl. 4 1998 S31 S32
34. C Mathelin P Walter M Gharbi B Viville B Gairar J.P. Brettes Is endometrial cytology of any use? Eur J Cancer 34 Suppl. 4 1998 S38 S39
35. L Van Hoe S Gryspeerdt H Bloemen Tamoxifen-induced changes of the uterus: MRI features Eur J Cancer 34 Suppl. 4 1998 S36 S37
36. P Neven X De Muylder Y Van Belle I Van Hooff G Vanderick Longitudinal hysteroscopic follow-up during tamoxifen treatment Lancet 1 1998 351 36
37. M Vosse F Renard D Hertens A.R. Grivegnée M Coibion Tamoxifen and endometrium: preliminary results of a follow-up study Eur J Cancer 34 Suppl. 4 1998 S33 S34
38. M Whitehead A randomised pilot study of hormone replacement therapy (HRT) in breast cancer patients: the combined effects of tamoxifen and HRT on the endometrium Eur J Cancer 34 Suppl. 4 1998 S55
39. D Van Liedekerke R Gevers Ph De Sutler C Bourgain J.J. Amy Use of levonorgestrel intrauterine device for prevention of endometrial changes induced by tamoxifen Eur J Cancer 34 Suppl. 4 1998 S55 S56
40. E Tomás Toremifene and the uterus Eur J Cancer 34 Suppl. 4 1998 S58
41. R O'Regan A Cisneros V.C. Jordan Is there life after tamoxifen? New anti-oestrogens Eur J Cancer 34 Suppl. 4 1998 S57 S58
42. P.D. Delmas N.H. Bjarnsson B.H. Mitlak Effects of raloxifene on bone mineral density, serum cholesterol concentrations and uterine endometrium in postmenopausal women N Engl J Med 337 1997 1641 1647